IDEXX Laboratories Inc (IDXX) stock
IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$698.47+8.23 (+1.19%)
Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –
IDEXX Laboratories total assets
Total assets on the balance sheet at the end of each period.
IDEXX Laboratories's total assets was $3.44B at Jun 30, 2026. For fiscal 2025 it was $3.35B, up 1.7% from the year before. Over ten years it grew 8.6% a year on average. The highest annual figure on record is $3.35B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.35B | +1.7% |
| FY2024 | Dec 31, 2024 | $3.29B | +1.0% |
| FY2023 | Dec 31, 2023 | $3.26B | +18.7% |
| FY2022 | Dec 31, 2022 | $2.75B | +12.7% |
| FY2021 | Dec 31, 2021 | $2.44B | +6.2% |
| FY2020 | Dec 31, 2020 | $2.29B | +25.2% |
| FY2019 | Dec 31, 2019 | $1.83B | +19.2% |
| FY2018 | Dec 31, 2018 | $1.54B | -10.3% |
| FY2017 | Dec 31, 2017 | $1.71B | +11.9% |
| FY2016 | Dec 31, 2016 | $1.53B | +3.8% |
| FY2015 | Dec 31, 2015 | $1.47B | +6.6% |
| FY2014 | Dec 31, 2014 | $1.38B | +12.5% |
| FY2013 | Dec 31, 2013 | $1.23B | +11.5% |
| FY2012 | Dec 31, 2012 | $1.10B | +7.1% |
| FY2011 | Dec 31, 2011 | $1.03B | +14.9% |
| FY2010 | Dec 31, 2010 | $897.14M | +11.0% |
| FY2009 | Dec 31, 2009 | $808.53M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.44B | +3.3% |
| Q1 FY2026 | Mar 31, 2026 | $3.39B | +5.3% |
| Q4 FY2025 | Dec 31, 2025 | $3.35B | +1.7% |
| Q3 FY2025 | Sep 30, 2025 | $3.39B | +1.1% |
| Q2 FY2025 | Jun 30, 2025 | $3.33B | -2.5% |
| Q1 FY2025 | Mar 31, 2025 | $3.21B | -4.2% |
| Q4 FY2024 | Dec 31, 2024 | $3.29B | +1.0% |
| Q3 FY2024 | Sep 30, 2024 | $3.35B | +8.6% |
| Q2 FY2024 | Jun 30, 2024 | $3.41B | +19.0% |
| Q1 FY2024 | Mar 31, 2024 | $3.35B | +19.4% |
| Q4 FY2023 | Dec 31, 2023 | $3.26B | +18.7% |
| Q3 FY2023 | Sep 30, 2023 | $3.09B | +16.9% |
| Q2 FY2023 | Jun 30, 2023 | $2.87B | +10.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.81B | +8.3% |
| Q4 FY2022 | Dec 31, 2022 | $2.75B | +12.7% |
| Q3 FY2022 | Sep 30, 2022 | $2.64B | +10.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.61B | +8.1% |
| Q1 FY2022 | Mar 31, 2022 | $2.59B | +11.4% |
| Q4 FY2021 | Dec 31, 2021 | $2.44B | +6.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.39B | +16.5% |
| Q2 FY2021 | Jun 30, 2021 | $2.41B | +23.0% |
| Q1 FY2021 | Mar 31, 2021 | $2.33B | +23.4% |
| Q4 FY2020 | Dec 31, 2020 | $2.29B | +25.2% |
| Q3 FY2020 | Sep 30, 2020 | $2.05B | +16.9% |
| Q2 FY2020 | Jun 30, 2020 | $1.96B | +13.7% |
| Q1 FY2020 | Mar 31, 2020 | $1.89B | +12.2% |
| Q4 FY2019 | Dec 31, 2019 | $1.83B | +19.2% |
| Q3 FY2019 | Sep 30, 2019 | $1.75B | +13.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.72B | +13.4% |
| Q1 FY2019 | Mar 31, 2019 | $1.68B | +14.4% |
| Q4 FY2018 | Dec 31, 2018 | $1.54B | -10.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.54B | -7.5% |
| Q2 FY2018 | Jun 30, 2018 | $1.52B | -7.1% |
| Q1 FY2018 | Mar 31, 2018 | $1.47B | -6.5% |
| Q4 FY2017 | Dec 31, 2017 | $1.71B | +11.9% |
| Q3 FY2017 | Sep 30, 2017 | $1.67B | +11.3% |
| Q2 FY2017 | Jun 30, 2017 | $1.64B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.57B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.53B | – |
| Q3 FY2016 | Sep 30, 2016 | $1.50B | – |
See a number that looks wrong?